Charles River Laboratories International, Inc. (CRL) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Charles River Laboratories International financial statements at a glance

Charles River Laboratories International reported revenue of $4.02 billion for fiscal year 2025 (ended December 31, 2025), down 0.9% from fiscal year 2024. Net income was -$144.34 million, a net margin of 3.6% loss, and diluted earnings per share were -$2.91.

At the end of fiscal year 2025 it had total assets of $7.14 billion, total liabilities of $3.92 billion and shareholders' equity of $3.16 billion, with cash and short-term investments of $213.77 million and total debt of $2.57 billion.

Its operations brought in $737.65 million of cash; capital spending was $219.15 million, leaving free cash flow of $518.49 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

CRL logo

Charles River Laboratories International, Inc.

CRLUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
4.02B
Prev Year: 4.05B
YoY: -0.9%
Operating Revenue
4.02B
Prev Year: 4.05B
YoY: -0.9%
Net Income from Continuing Operation Net Minority Interest
-144.34M
Prev Year: 22.20M
YoY: -750.1%
Total Unusual Items Excluding Goodwill
-375.97M
Prev Year: -215.00M
YoY: -74.9%
Total Unusual Items
-375.97M
Prev Year: -215.00M
YoY: -74.9%
Normalized EBITDA
786.81M
Prev Year: 796.14M
YoY: -1.2%
Tax Rate for Calcs
0.21
Prev Year: 0
Tax Effect of Unusual Items
-78.95M
Prev Year: -45.15M
YoY: -74.9%
Impairment of Capital Assets
375.97M
Prev Year: 215.00M
YoY: +74.9%
Depreciation Amortization Depletion
179.07M
Prev Year: 138.47M
YoY: +29.3%
Depreciation and amortization
179.07M
Prev Year: 138.47M
YoY: +29.3%
Amortization
179.07M
Prev Year: 138.47M
YoY: +29.3%
Amortization of Intangibles
179.07M
Prev Year: 138.47M
YoY: +29.3%
Cost of Revenue
2.69B
Prev Year: 2.72B
YoY: -1.0%
Gross Profit
1.32B
Prev Year: 1.33B
YoY: -0.6%
Operating Expense
922.14M
Prev Year: 889.47M
YoY: +3.7%
Selling General and Administrative
743.07M
Prev Year: 751.00M
YoY: -1.1%
Operating Income
401.14M
Prev Year: 442.35M
YoY: -9.3%
Net Non Operating Interest Income Expense
-102.09M
Prev Year: -117.71M
YoY: +13.3%
Non-operating Interest Income
4.94M
Prev Year: 8.57M
YoY: -42.4%
Non-operating Interest Expense
107.03M
Prev Year: 126.29M
YoY: -15.3%
Other Income Expense
-398.55M
Prev Year: -231.52M
YoY: -72.1%
Special Income Charges
-375.97M
Prev Year: -215.00M
YoY: -74.9%
Other Non-operating Income (expense)
-22.58M
Prev Year: -16.52M
YoY: -36.7%
Pre-tax Income
-99.50M
Prev Year: 93.11M
YoY: -206.9%
Provision for Income Taxes
42.66M
Prev Year: 67.82M
YoY: -37.1%
Net Income Common Stockholders
-144.34M
Prev Year: 10.30M
YoY: -1501.7%
Net Income
-144.34M
Prev Year: 22.20M
YoY: -750.1%
Net Income Including Non-Controlling Interests
-142.16M
Prev Year: 25.29M
YoY: -662.1%
Net Income from Continuing Operations
-142.16M
Prev Year: 25.29M
YoY: -662.1%
Noncontrolling Interests
-2.17M
Prev Year: -3.09M
YoY: +29.6%
Diluted NI Available to Com Stockholders
-144.34M
Prev Year: 10.30M
YoY: -1501.7%
Basic EPS
-2.91
Prev Year: 0.2
YoY: -1555.0%
Diluted EPS
-2.91
Prev Year: 0.2
YoY: -1555.0%
Weighted Average Shares (basic)
49.56M
Prev Year: 51.38M
YoY: -3.5%
Weighted Average Shares (diluted)
49.56M
Prev Year: 51.63M
YoY: -4.0%
Total Operating Income as Reported
25.16M
Prev Year: 227.35M
YoY: -88.9%
Total Expenses
3.61B
Prev Year: 3.61B
YoY: +0.2%
Net Income from Continuing and Discontinued Operation
-144.34M
Prev Year: 22.20M
YoY: -750.1%
Normalized Income
152.68M
Prev Year: 192.05M
YoY: -20.5%
Interest Income
4.94M
Prev Year: 8.57M
YoY: -42.4%
Interest Expense
107.03M
Prev Year: 126.29M
YoY: -15.3%
Net Interest Income
-102.09M
Prev Year: -117.71M
YoY: +13.3%
EBIT
7.53M
Prev Year: 219.40M
YoY: -96.6%
EBITDA
410.84M
Prev Year: 581.14M
YoY: -29.3%
Reconciled Cost of Revenue
2.47B
Prev Year: 2.49B
YoY: -1.1%
Reconciled Depreciation
403.31M
Prev Year: 361.74M
YoY: +11.5%
Values in USD

Charles River Laboratories International key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$4.0B$4.0B$4.1B$4.0B$3.5B
Gross profit$1.3B$1.3B$1.5B$1.5B$1.3B
Operating income$401.1M$442.3M$617.3M$651.0M$589.9M
Net income-$144.3M$10.3M$474.6M$486.2M$391.0M
Diluted EPS-$2.91$0.20$9.22$9.48$7.60
Total assets$7.1B$7.5B$8.2B$7.6B$7.0B
Total liabilities$3.9B$4.0B$4.5B$4.6B$4.4B
Shareholders' equity$3.2B$3.5B$3.6B$3.0B$2.5B
Cash and short-term investments$213.8M$194.6M$276.8M$233.9M$241.2M
Total debt$2.6B$2.7B$3.1B$3.1B$2.9B
Operating cash flow$737.6M$734.6M$683.9M$619.6M$760.8M
Capital spending$219.2M$233.0M$318.5M$324.7M$228.8M
Free cash flow$518.5M$501.6M$365.4M$294.9M$532.0M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Charles River Laboratories International's revenue in fiscal year 2025?

$4.02 billion, down 0.9% from $4.05 billion in fiscal year 2024.

How much profit does Charles River Laboratories International make?

Charles River Laboratories International reported net income of -$144.34 million for fiscal year 2025 (3.6% of revenue); operating income was $401.14 million.

How much cash and debt does Charles River Laboratories International have?

At the end of fiscal year 2025: cash and short-term investments of $213.77 million and total debt of $2.57 billion.

What is Charles River Laboratories International's free cash flow?

$518.49 million in fiscal year 2025 (operating cash flow of $737.65 million minus capital spending of $219.15 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube